Company Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States.
The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A.
The company was founded in 2014 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 39 |
| CEO | Thomas Schuetz |
Contact Details
Address: 80 Guest Street, Suite 601 Boston, Massachusetts 02135 United States | |
| Phone | 617 500 8099 |
| Website | compasstherapeutics.com |
Stock Details
| Ticker Symbol | CMPX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1738021 |
| CUSIP Number | 20454B104 |
| ISIN Number | US20454B1044 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Thomas J. Schuetz M.D., Ph.D. | Chief Executive Officer and Vice Chairman |
| Barry Shin J.D., M.B.A. | Chief Financial Officer |
| Jonathan E. Anderman J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Bing Gong Ph.D. | Chief Scientific Officer |
| Karin Herrera B.A. | Senior Vice President and Head of Clinical Operations |
| Dr. James Kranz Ph.D. | Vice President and Head of Chemistry Manufacturing and Controls |
| Dr. Cynthia A. Sirard M.D., Ph.D. | Chief Medical Officer |
| Arjun Prasad M.B.A., M.P.H. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 5, 2026 | 10-Q | Quarterly Report |
| May 5, 2026 | 8-K | Current Report |
| Apr 29, 2026 | ARS | Filing |
| Apr 29, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 27, 2026 | 8-K | Current Report |
| Mar 12, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 5, 2026 | 10-K | Annual Report |
| Mar 5, 2026 | 8-K | Current Report |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |